GENF, 12. Juni 2018 /PRNewswire/ — DyAnsys Europe SARL hat bekannt gegeben, dass seine Muttergesellschaft, DyAnsys Inc., die Zulassung der U. S. Food and Drug Administration für
GINEBRA, 12 de junio de 2018 /PRNewswire/ — DyAnsys Europe SARL ha anunciado que su empresa matriz, DyAnsys Inc., cuenta con la aprobación de la Administración
San Mateo, Ca — DyAnsys Inc. announced that the U.S. Food and Drug Administration has cleared its auricular neurostimulation device, Drug Relief®, to be used
GENÈVE, 12 juin 2018 /PRNewswire/ — DyAnsys Europe SARL a annoncé que sa société mère, DyAnsys Inc., a obtenu l’autorisation de la Food and Drug Administration américaine
At DyAnsys, patient safety is a primary concern and focus during product development as well as when products are in use. Chief Executive Officer Srini Nageshwar
When patients come in for a Primary Relief® treatment, they see a conveniently packaged system powered by a hand-held device that appears to be little more
9th International Auriculotherapy Symposium Offers New Insights and Scientific Update Insights from DyAnsys Chief Executive Srini Nageshwar In recent years, pioneers in the field of auriculotherapy
Health Care Leaders Call for Accelerated Research to End Opioid Crisis National Institutes of Health leaders took a remarkable step recently in calling for an
Health care providers can learn more about the condition of their patients and monitor the effectiveness of various treatments by measuring the Autonomic Nervous System.
Revelations from Primary Relief® Development and Treatment Opportunities Insights into discoveries made during the development of a non-narcotic pain treatment system along with comprehensive information on how
GENF, 12. Juni 2018 /PRNewswire/ — DyAnsys Europe SARL hat bekannt gegeben, dass seine Muttergesellschaft, DyAnsys Inc., die Zulassung der U. S. Food and Drug Administration für
GINEBRA, 12 de junio de 2018 /PRNewswire/ — DyAnsys Europe SARL ha anunciado que su empresa matriz, DyAnsys Inc., cuenta con la aprobación de la Administración
San Mateo, Ca — DyAnsys Inc. announced that the U.S. Food and Drug Administration has cleared its auricular neurostimulation device, Drug Relief®, to be used
GENÈVE, 12 juin 2018 /PRNewswire/ — DyAnsys Europe SARL a annoncé que sa société mère, DyAnsys Inc., a obtenu l’autorisation de la Food and Drug Administration américaine
At DyAnsys, patient safety is a primary concern and focus during product development as well as when products are in use. Chief Executive Officer Srini Nageshwar
When patients come in for a Primary Relief® treatment, they see a conveniently packaged system powered by a hand-held device that appears to be little more
9th International Auriculotherapy Symposium Offers New Insights and Scientific Update Insights from DyAnsys Chief Executive Srini Nageshwar In recent years, pioneers in the field of auriculotherapy
Health Care Leaders Call for Accelerated Research to End Opioid Crisis National Institutes of Health leaders took a remarkable step recently in calling for an
Health care providers can learn more about the condition of their patients and monitor the effectiveness of various treatments by measuring the Autonomic Nervous System.
Revelations from Primary Relief® Development and Treatment Opportunities Insights into discoveries made during the development of a non-narcotic pain treatment system along with comprehensive information on how
GENF, 12. Juni 2018 /PRNewswire/ — DyAnsys Europe SARL hat bekannt gegeben, dass seine Muttergesellschaft, DyAnsys Inc., die Zulassung der U. S. Food and Drug Administration für
GINEBRA, 12 de junio de 2018 /PRNewswire/ — DyAnsys Europe SARL ha anunciado que su empresa matriz, DyAnsys Inc., cuenta con la aprobación de la Administración
San Mateo, Ca — DyAnsys Inc. announced that the U.S. Food and Drug Administration has cleared its auricular neurostimulation device, Drug Relief®, to be used
GENÈVE, 12 juin 2018 /PRNewswire/ — DyAnsys Europe SARL a annoncé que sa société mère, DyAnsys Inc., a obtenu l’autorisation de la Food and Drug Administration américaine
At DyAnsys, patient safety is a primary concern and focus during product development as well as when products are in use. Chief Executive Officer Srini Nageshwar
When patients come in for a Primary Relief® treatment, they see a conveniently packaged system powered by a hand-held device that appears to be little more
9th International Auriculotherapy Symposium Offers New Insights and Scientific Update Insights from DyAnsys Chief Executive Srini Nageshwar In recent years, pioneers in the field of auriculotherapy
Health Care Leaders Call for Accelerated Research to End Opioid Crisis National Institutes of Health leaders took a remarkable step recently in calling for an
Health care providers can learn more about the condition of their patients and monitor the effectiveness of various treatments by measuring the Autonomic Nervous System.
Revelations from Primary Relief® Development and Treatment Opportunities Insights into discoveries made during the development of a non-narcotic pain treatment system along with comprehensive information on how
Non-invasive neurostimulation devices for chronic pain, opioid withdrawal, and autonomic care.
© 2026 NeuroStimulation Medtech Pvt. Ltd. All rights reserved.